Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp

Bullboard Posts

Post by PutinKhuylo1on Nov 06, 2017 11:30am

146 Views

Post# 26911803

David Moore

"David Moore, appointed Senior Vice President, Commercial, in August 2017, joined Novo Nordisk as Senior Vice President of Marketing in May 2017. He is the key leader for Novo Nordisk’s sales and marketing team across its diabetes, obesity, hemophilia and growth hormone portfolios. In this role, he oversees commercial operations including sales, brand strategies and initiatives to enhance the company’s growth and presence in the United States."

Bullboard Posts

Corus reports Q1 profit drop in the face of falling revenue